Search results
Startling Discovery: Young Diabetics Show Early Signs of Alzheimer’s Disease
SciTechDaily· 7 days agoA study from CU Anschutz indicates that diabetes beginning in youth may increase the risk of...
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine...
WJTV Jackson· 2 days agoNeuroSense Therapeutics (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today announced that ...
Stealthy Durham firm emerges with $14 million to discover new drugs
The Business Journals· 6 days agoA new company in Durham aims to accelerate the drug discovery process. Avicenna Biosciences recently...
Study uncovers protein interactions as a potential path for ALS cure
Medical Xpress· 2 days agoALS, also known as Lou Gehrig's disease, is a debilitating neurodegenerative condition that progressively impairs nerve cells responsible for muscle control ...
AlzeCure Reports Anti-Inflammatory Effects with NeuroRestore ACD856 with Relevance to Alzheimer's...
Digital Journal· 3 days agoSTOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases ...
Why Creatine Is The Missing Ingredient In Your Wellness Routine
Women's Health via Yahoo News· 5 days agoCreatine has benefits such as increasing energy, exercise capacity, and lean body mass. Experts...
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
Zacks· 2 days agoFree Report) announced that it has signed a collaboration and option-to-license agreement with New York-based privately held biotech Gilgamesh Pharmaceuticals to research and develop next-generation ...
Why do people with dementia 'come back’ before death?
Cosmos· 6 days agoAlthough the person is still alive, dementia slowly and irreversibly chips away at their memories...
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March...
WKBN 27 Youngstown· 1 day agoBioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion (approximately SEK 4 billion) for their fiscal year (FY) 2024 ...
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Digital Journal· 2 days agoTop-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a